Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:25109669  

The first knockin mouse model of episodic ataxia type 2.

Samuel J Rose | Lisa H Kriener | Ann K Heinzer | Xueliang Fan | Robert S Raike | Arn M J M van den Maagdenberg | Ellen J Hess
Experimental neurology | 2014

Episodic ataxia type 2 (EA2) is an autosomal dominant disorder associated with attacks of ataxia that are typically precipitated by stress, ethanol, caffeine or exercise. EA2 is caused by loss-of-function mutations in the CACNA1A gene, which encodes the α1A subunit of the CaV2.1 voltage-gated Ca(2+) channel. To better understand the pathomechanisms of this disorder in vivo, we created the first genetic animal model of EA2 by engineering a mouse line carrying the EA2-causing c.4486T>G (p.F1406C) missense mutation in the orthologous mouse Cacna1a gene. Mice homozygous for the mutated allele exhibit a ~70% reduction in CaV2.1 current density in Purkinje cells, though surprisingly do not exhibit an overt motor phenotype. Mice hemizygous for the knockin allele (EA2/- mice) did exhibit motor dysfunction measurable by rotarod and pole test. Studies using Cre-flox conditional genetics explored the role of cerebellar Purkinje cells or cerebellar granule cells in the poor motor performance of EA2/- mice and demonstrate that manipulation of either cell type alone did not cause poor motor performance. Thus, it is possible that subtle dysfunction arising from multiple cell types is necessary for the expression of certain ataxia syndromes.

Pubmed ID: 25109669

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NINDS NIH HHS, United States
    Id: NS058596
  • Agency: NIGMS NIH HHS, United States
    Id: T32GM08605
  • Agency: NINDS NIH HHS, United States
    Id: NS33592
  • Agency: NINDS NIH HHS, United States
    Id: T32NS007480
  • Agency: NINDS NIH HHS, United States
    Id: R29 NS033592
  • Agency: NINDS NIH HHS, United States
    Id: T32 NS007480
  • Agency: NIGMS NIH HHS, United States
    Id: T32 GM008605
  • Agency: NINDS NIH HHS, United States
    Id: R21 NS058596
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS033592

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Cell Signaling Technology (tool)

RRID:SCR_004431

Privately held company that develops and produces antibodies, ELISA kits, ChIP kits, proteomic kits, and other related reagents used to study cell signaling pathways that impact human health.

View all literature mentions